跳到正文
原文
MedPage Today·· 8 天前精选AI 评分75

评估和管理HIV患者更高的心血管疾病风险

Assessing and Managing HIV's Higher Heart Disease Risks

AI 导读

HIV患者心血管疾病风险是传统因素的两倍,随机对照试验REPRIEVE显示他汀类药物可降低36%的心血管事件风险。美国心脏协会等机构发布了针对HIV患者的他汀类药物使用指南。

推荐理由

介绍了HIV患者心血管疾病风险的研究进展,特别是关于使用他汀类药物的随机对照试验结果。

正文 · AI 翻译

译文尚不完整,完整内容请切换到原文。

— HIV感染者患心血管疾病的风险是普通人的两倍。

2026年11月11日 • 4 min read

了解HIV如何影响心血管疾病的风险可以帮助临床医生根据患者的需求定制护理,这从大多数HIV感染者的他汀类药物治疗开始。

"HIV holds its own as a risk factor for developing cardiovascular disease," Virginia Triant, MD, MPH, of Massachusetts General Hospital in Boston, said in a presentation at the IDWeek annual meeting.

A 2018 meta-analysis showed that people living with HIV were twice as likely to develop cardiovascular disease as those without HIV, Triant observed. Those with HIV also faced greater risks of myocardial infarction and stroke she added, putting HIV nearly on par with the cardiovascular relative risks found in the INTERHEART study for hypertension, diabetes, and smoking.

传统因素在与HIV相关的心血管风险中起作用。Triant指出,HIV感染者高血压、糖尿病和血脂异常的发病率高于无HIV感染者的水平。研究还显示,HIV感染者中有85%的吸烟史。

抗逆转录病毒治疗与风险

这并不能解释整个故事,Triant指出。抗逆转录病毒治疗本身也带来了一定的心血管风险。

Early protease inhibitors like darunavir were linked with cumulative myocardial infarction risks, and recent use of the nucleoside reverse transcriptase inhibitor abacavir was tied to increased myocardial infarction risk. It's not clear whether integrase strand transfer inhibitors also boost cardiovascular risk, with conflicting results from the RESPOND and HIV-CAUSAL studies.

在调整传统风险因素和抗逆转录病毒治疗后,Triant表示,心血管风险拼图中仍然缺少一块。这块拼图可能是HIV伴随的炎症。

The SMART study pointed to inflammation's role in cardiovascular disease, she noted. An analysis of data from the REPRIEVE study reinforced inflammation's role, even in people with well-controlled HIV and low to moderate cardiovascular risk.

个性化治疗

尽管对HIV如何独特地影响心血管风险有了越来越深入的理解,Triant表示,“这直到最近才转化为针对HIV感染者的不同和个性化的临床指导。”“我认为这在为HIV感染者提供公平的心血管护理方面是一个挑战。”

现有的针对一般人群的心血管风险预测评分在HIV感染者中效果不佳,仅考虑了传统风险因素,而未包括HIV相关的因素,Triant说。即使在HIV感染者中,心血管风险也因性别、种族、民族和地理位置而异。

Among those with HIV, the Pooled Cohort Equations (PCE) that debuted in 2013 underestimated cardiovascular risk in women and those in low to moderate risk groups. The more comprehensive 2023 PREVENT equations mirrored the PCE risk underestimation for people with HIV, with major adverse cardiovascular events (MACE) rates greater than PREVENT predictions.

鉴于低估的风险,HIV感染者接受符合指南的心血管预防护理的可能性较低,Triant 表示。她指出,一般人群的指南所需的标准也低于HIV感染者的标准。

That began to change with cholesterol guidelines from the American Health Association (AHA) and other groups that added consideration of HIV as a cardiovascular disease risk factor. A 2019 AHA scientific statement that specifically focused on people with HIV highlighted risk-enhancing factors such as prolonged viremia, low CD4 counts, delays in starting antiretroviral therapy (ART), and metabolic syndrome.

然而,Triant 表示,“真正缺失的是一个大型临床试验,能够提供支持HIV感染者心血管预防的推荐的坚实数据。”

普遍推荐

Then came REPRIEVE in 2023. That phase III clinical trial included only people with HIV on ART who had low to moderate cardiovascular disease risk and didn't meet general guidelines' thresholds for statin therapy. REPRIEVE showed that statin therapy was linked to a 36% reduction in MACE risk compared with placebo.

这些结果并非由亚组驱动。“无论你是从人口统计学、传统风险因素还是传统HIV相关因素来看,都是降低风险,”Triant 解释道。”

REPRIEVE was the first randomized trial that showed a cardiovascular prevention benefit that was different from the general population. "This is really paradigm-shifting," she noted. A CDC analysis found that full implementation of REPRIEVE's approach in people with HIV and low to moderate cardiovascular disease risk could lead to 7,418 fewer first major adverse cardiovascular events over 5 years.

Triant 表示,REPRIEVE的研究结果促使了HIV感染者的实践改变指南。

In 2024, an HHS panel rolled out recommendations calling for daily moderate-intensity statins in people with HIV ages 40 to 75 years with low to intermediate (less than 20%) 10-year risk of atherosclerotic cardiovascular disease (ASCVD). In those with less than 5% risk, the HHS panel favored starting at least moderate-intensity statins.

The American College of Cardiology and other societies followed that with a dyslipidemia guideline in 2026 that recommended that everyone with HIV ages 40 to 75 years on ART receive statin therapy to reduce ASCVD event risk and slow coronary atherosclerosis.

"这真是一个引人注目的建议,对于该领域来说非常重要,”Triant 解释道。“值得注意的是,这与计算的基础风险无关,与LDL无关,对于这个年龄段的人来说都是如此。”

她补充说,临床医生可能需要考虑在30岁时就开始给HIV感染者服用他汀类药物。“即使我们没有试验数据,我强烈认为HIV应该被视为ASCVD风险增强因素,即使在那个年龄也是如此,”Triant 说。

即使有了这些新调整的指南,实施起来仍会面临挑战,她指出。在REPRIEVE之前,HIV感染者中符合他汀类药物使用标准的患者中只有80%的人接受了他汀类药物治疗。

"消除我们所知的心血管预防和护理中的不平等现象仍然是一个关键挑战,”Triant 表示。“最近的指南可能会对HIV感染者产生实践改变,但前提是必须大规模实施。”

来源:MedPage Today · medpagetoday.com